Abstract: A method of braiding a stent includes braiding a number of elongate filaments around a mandrel using tensioned braiding carriers without spooling the filaments to the tensioned braiding carriers to form a braided stent having atraumatic ends.

Abstract: Provided herein is a bioconjugate comprising a K. pneumoniae O-antigen covalently linked to a fusion protein comprising a ComP protein or a glycosylation tag fragment. The K. pneumoniae O-antigen bioconjugate of this disclosure can be used as a conjugate vaccine including multivalent conjugate vaccines comprising multiple K. pneumoniae O-antigens.

Abstract: An intravascular device, such as a stylet or catheter, having a flexible, atraumatic tip is disclosed. The intravascular device includes an elongate member having a proximal end, a distal end, and an inner lumen extending between the proximal end and the distal end; a ring electrode disposed at the distal end of the elongate member; an ultrasound sensor disposed at a distal end of the ring electrode; and a first electrical conductor configured to convey an electrocardiogram signal from the ring electrode to a processor. The first electrical conductor may comprise a tapered distal segment or a braided segment.

Abstract: An intravascular device, such as a stylet or catheter, having a flexible, atraumatic tip is disclosed. The intravascular device includes an elongate member having a proximal end, a distal end, and an inner lumen extending between the proximal end and the distal end; a ring electrode disposed at the distal end of the elongate member; an ultrasound sensor disposed at a distal end of the ring electrode; and a first electrical conductor configured to convey an electrocardiogram signal from the ring electrode to a processor. The first electrical conductor may comprise a tapered distal segment or a braided segment.

Abstract: An intravascular device, such as a stylet or catheter, having a flexible, atraumatic tip is disclosed. The intravascular device includes an elongate member having a proximal end, a distal end, and an inner lumen extending between the proximal end and the distal end; a ring electrode disposed at the distal end of the elongate member; an ultrasound sensor disposed at a distal end of the ring electrode; and a first electrical conductor configured to convey an electrocardiogram signal from the ring electrode to a processor. The first electrical conductor may comprise a tapered distal segment or a braided segment.

Abstract: Feet for a multi-position computing device are described. In one or more implementations, a multi-position computing device is configured to include a base and a display device connected to the base by a hinge mechanism. The hinge mechanism is operable to position the display device into multiple positions relative to the base including at least an upright position and a laid-down position. An arrangement of feet on the underside of the base is designed to facilitate dynamic movement of the device into the multiple positions. The arrangement of feet includes sliding feet that engage for sliding of the base across a surface when pressure is applied to the hinge mechanism for transitions between positions. The arrangement of feet also includes tacky feet that engage and resist sliding of the base across the surface in the absence of pressure applied to the hinge mechanism.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I) or salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I), salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections:

Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.

Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.

Abstract: The present invention relates to viral polymerase inhibitors of formula (I), salts, N-oxides, solvates, hydrates, racemates, enantiomers or isomers thereof, processes for their preparation and their use in the treatment of Flaviviridae viral infections such as Hepatitis C virus (HCV) infections:

Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.

Abstract: The present disclosure relates to the use and methods of manufacture of bicyclic nucleosides and nucleotides for the treatment and prevention of infectious and proliferative diseases, including microbial infections and cancer.